Alfresa Holdings
Alfresa Holdings Corporation, commonly referred to as Alfresa, is a prominent player in the pharmaceutical distribution industry, headquartered in Osaka, Japan. Established in 2003, the company has rapidly expanded its operations across Asia, particularly in Japan and other key regions, solidifying its position as a leading distributor of pharmaceuticals and healthcare products. Alfresa's core business areas include the wholesale distribution of prescription drugs, over-the-counter medications, and medical supplies. The company is distinguished by its commitment to quality and efficiency, ensuring that healthcare providers have access to essential products. With a strong market presence, Alfresa has achieved notable milestones, including strategic partnerships and a robust logistics network, enhancing its service delivery and customer satisfaction.
DitchCarbon Score
How does Alfresa Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alfresa Holdings's score of 41 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alfresa Holdings's reported carbon emissions
In 2023, Alfresa Holdings reported total carbon emissions of approximately 69,082 tonnes CO2e, comprising about 32,399 tonnes CO2e from Scope 1 and about 36,683 tonnes CO2e from Scope 2. This marks a slight decrease from 2022, where total emissions were around 141,020 tonnes CO2e. Alfresa has set ambitious climate commitments, aiming for a 10% reduction in Scope 1 and Scope 2 emissions by the end of FY2024, using FY2020 emissions as a baseline. Furthermore, the company targets a 30% reduction by the end of FY2030, with a long-term goal of achieving carbon neutrality by 2050. These initiatives reflect Alfresa's commitment to addressing climate change and reducing its carbon footprint in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 20,776,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 99,833,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alfresa Holdings is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
